Berenshteyn, F.; Lacoste A.; Thomas, J.R.; Roma, G.; Michaud, G.A.; Tseng,
B.S.; Porter, J.A.; Myer, V.E.; Tallarico, J.A.; Hamann, L.G.; Curtis, D.;
Fishman, M.C.; Dietrich, W.F.; Dales, N.A.; Sivasankaran, R. SMN2 splice
modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat
Chem Biol. 2015, 11(7), 511-517. (c) Naryshkin, N.A.; Weetall, M.; Dakka,
A.; Narasimhan, J.; Zhao, X.; Feng, Z.; Ling, K.K.; Karp, G.M.; Qi, H.; Woll,
M.G.; Chen, G.; Zhang, N.; Gabbeta, V.; Vazirani, P.; Bhattacharyya, A.;
Furia, B.; Risher, N.; Sheedy, J.; Kong, R.; Ma, J.; Turpoff, A.; Lee, C.S.;
Zhang, X.; Moon, Y.C.; Trifillis, P.; Welch, E.M.; Colacino, J.M.; Babiak, J.;
Almstead, N.G.; Peltz, S.W.; Eng, L.A.; Chen, K.S.; Mull, J.L.; Lynes, M.S.;
Rubin, L.L.; Fontoura, P.; Santarelli, L.; Haehnke, D.; McCarthy, K.D.;
Schmucki, R.; Ebeling, M.; Sivaramakrishnan, M.; Ko, C.P.; Paushkin, S.V.;
Ratni, H.; Gerlach, I.; Ghosh, A.; Metzger, F. Motor neuron disease. SMN2
splicing modifiers improve motor function and longevity in mice with spinal
muscular atrophy. Science. 2014, 345(6197), 688-93. (d) Hastings, M.L.;
Berniac, J.; Liu, Y.H.; Abato, P.; Jodelka, F.M.; Barthel, L.; Kumar, S.;
Dudley, C.; Nelson, M.; Larson, K.; Edmonds, J.; Bowser, T.; Draper. M.;
Higgins, P.; Krainer. A.R. Tetracyclines that promote SMN2 exon 7 splicing
as therapeutics for spinal muscular atrophy. Sci Transl Med. 2009, 1(5),
5ra12.
15. (a) Douglas, A.G.; Wood, M.J. RNA splicing: disease and therapy. Brief
Funct Genomics. 2011, 10(3), 151-164. (b) Lagisetti, C.; Pourpak, A.;
Goronga, T.; Jiang, Q.; Cui, X.; Hyle, J.; Lahti, J.M.; Morris, S.W.; Webb,
T.R. Synthetic mRNA splicing modulator compounds with in vivo antitumor
activity. J Med Chem. 2009, 52(22), 6979-6990. (c) Kaida, D.; Motoyoshi,
H.; Tashiro, E.; Nojima, T.; Hagiwara, M.; Ishigami, K.; Watanabe, H.;
Kitahara, T.; Yoshida, T.; Nakajima, H.; Tani, T.; Horinouchi, S.; Yoshida,
M. Spliceostatin A targets SF3b and inhibits both splicing and nuclear
retention of pre-mRNA. Nat Chem Biol. 2007, 3, 576-583. (d) Kotake, Y.;
Sagane, K.; Owa, T.; Mimori-Kiyosue, Y.; Shimizu, H.; Uesugi, M.;
Ishihama, Y.; Iwata, M.; Mizui, Y. Splicing factor SF3b as a target of the
antitumor natural product pladienolide. Nat Chem Biol. 2007, 3, 570-575. (e)
O'Brien, K.; Matlin, A J.; Lowell, A.M.; Moore, M.J. The biflavonoid
isoginkgetin is a general inhibitor of Pre-mRNA splicing. J Biol Chem. 2008,
283, 33147-33154. (f) Fan, L.; Lagisetti, C.; Edwards, C.C.; Webb, T.R.;
Potter, P.M. Sudemycins, novel small molecule analogues of FR901464,
induce alternative gene splicing. ACS Chem Biol. 2011, 6, 582-589.
16. Fürstner, A.; Krause, H.; Thiel, O.R. Efficient relay syntheses and
assessment of the DNA-cleaving properties of the pyrrole alkaloid derivatives
permethyl storniamide A, lycogalic acid A dimethyl ester, and the halitulin
core. Tetrahedron, 2002, 58, 6373-6380.
Acknowledgments
We thank Emmanuel Panteris (Department of Botany, School
of Biology, Aristotle University of Thessaloniki) for help with
the immunofluoresence experiments.
References
1. (a) Gul, W.; Hamann, MT. Indole alkaloid marine natural products: An
established source of cancer drug leads with considerable promise for the
control of parasitic, neurological and other diseases. Life Sci. 2005, 78, 442-
453. (b) Hosoya, T.; Arai, M.A.; Koyano, T.; Kowithayakorn, T.; Ishibashi,
M. Naturally occurring small-molecule inhibitors of hedgehog/GLI-mediated
transcription. Chembiochem. 2008, 9, 1082-1092. (c) Kamata, K.; Kiyota, M.;
Naoe, A.; Nakatani, S.; Yamamoto, Y.; Hayashi, M.; Komiyama, K.; Yamori,
T.; Ishibashi. M. New bisindole alkaloids isolated from Myxomycetes
Arcyria cinerea and Lycogala epidendrum. Chem. Pharm. Bull. (Tokyo)
2005, 53, 594-597.
2. (a) Sánchez, C.; Méndez, C.; Salas, J.A.; Indolocarbazole natural products:
occurrence, biosynthesis, and biological activity. Nat. Prod. Rep. 2006, 23,
1007-1045. (b) Hosoya, T.; Yamamoto, Y.; Uehara, Y.; Hayashi, M.;
Komiyama, K.; Ishibashi, M. New cytotoxic bisindole alkaloids with protein
tyrosine kinase inhibitory activity from a myxomycete Lycogala epidendrum.
Bioorg. Med. Chem.Lett. 2005, 15, 2776-2780. (c) Hashimoto, T.; Yasuda,
A.; Akazawa, K.; Takaoka, S.; Tori, M.; Asakawa, Y. Three Novel Dimethyl
Pyrroledicarboxylate Lycogarubins A-C, from the Myxomycetes Lycogala
epidendrum, Tetrahedron Let. 1994, 35, 2559.
3. Gani, O.A.; Engh, R.A. Protein kinase inhibition of clinically important
staurosporine analogues. Nat. Prod. Rep. 2010, 27, 489-498.
4. Prudhomme, M. Rebeccamycin analogues as anti-cancer agents. Eur. J.
Med. Chem. 2003, 38, 123-140.
5. Schwandt, A.; Mekhail, T.; Halmos, B.; O'Brien, T.; Ma, P.C.; Fu, P.; Ivy,
P.; Dowlati, A. Phase-II trial of rebeccamycin analog, a dual topoisomerase-I
and -II inhibitor, in relapsed "sensitive" small cell lung cancer. J. Thorac
Oncol. 2012, 7(4), 751-754.
6. Nock, C.J.; Brell, J.M.; Bokar, J.A.; Cooney, M.M.; Cooper, B.; Gibbons,
J.; Krishnamurthi, S.; Manda, S.; Savvides, P.; Remick, S.C.; Ivy, P.;
Dowlati, A. A phase I study of rebeccamycin analog in combination with
oxaliplatin in patients with refractory solid tumors. Invest New Drugs. 2011,
29(1), 126-130.
7. Dowlati, A.; Posey, J.; Ramanathan, R.K.; Rath, L.; Fu, P.; Chak, A.;
Krishnamurthi, S.; Brell, J.; Ingalls, S.; Hoppel, C.L. Ivy, P.; Remick, S.C.
Phase II and pharmacokinetic trial of rebeccamycin analog in advanced
biliary cancers. Cancer Chemother Pharmacol. 2009, 65(1), 73-78.
8. McArthur, K.A.; Mitchell, S.S.; Tsueng, G.; Rheingold, A.; White, D.J.;
17. Schmuck, C. Self-assembly of 2-guanidiniocarbonyl)-pyrrole-4-
carboxylate in dimethyl sulfoxide: an entropy driven oligomerization,
Tetrahedron, 2001, 57, 3063-3067.
18. Barker, P.; Gendler, P.; Rapoport, H. 2-(Trichloroacetyl)pyrroles as
intermediates in the preparation of 2,4-disubstituted pyrroles. J. Org. Chem.,
1978, 43(25), 4849–4853.
19. Mothes, C.; Lavielle, S.; Karoyan P. Amino-Zinc-Ene-Enolate
Cyclization: A Short Access to cis-3-Substituted Prolino-homotryptophane
Derivatives. J. Org. Chem. 2008, 73, 6706–6710.
20. Merkul, E.; Schäfer, E.; Müller, T.J. Rapid synthesis of bis(hetero)aryls
by one-pot Masuda borylation-Suzuki coupling sequence and its application
to concise total syntheses of meridianins A and G. Org. Biomol. Chem. 2011,
9(9), 3139-3141.
21. Sumanasekera, C.; Watt, D.S.; Stamm, S. Substances that can change
alternative splice-site selection. Biochem. Soc. Trans. 2008, 36, 483-490.
22. Pawellek, A.; McElroy, S.; Samatov, T.; Mitchell, L.; Woodland, A.;
Ryder, U.; Gray, D.; Lührmann, R.; Lamond, AI. Identification of small
molecule inhibitors of pre-mRNA splicing. J. Biol. Chem. 2014, 289, 34683-
3498.
23. Kumar, D.; Kashyap, M.K.; La Clair, J.J.; Villa, R.; Spaanderman, I.;
Chien, S.; Rassenti, L.Z.; Kipps, T.J.; Burkart, M.D.; Castro, J.E. Selectivity
in Small Molecule Splicing Modulation. ACS Chem. Biol. 2016, In Press.
24. Pilch, B.; Allemand, E.; Facompré, M.; Bailly, C.; Riou, J.F.; Soret, J.;
Tazi, J. Specific inhibition of serine- and arginine-rich splicing factors
phosphorylation, spliceosome assembly, and splicing by the antitumor drug
NB-506. Cancer Res. 2001, 61(18), 6876-6884.
Grodberg, J.; Lam, K.S.; Potts, B.C. Lynamicins A-E, chlorinated bisindole
pyrrole antibiotics from a novel marine actinomycete. J. Nat. Prod. 2008, 71,
1732-1737.
9. Zhang, W; Liu, Z.; Li, S.; Yang, T.; Zhang, Q.; Ma, L.; Tian, X.; Zhang,
H.; Huang, C.; Zhang, S.; Ju, J.; Shen, Y.; Zhang, C. Spiroindimicins A-D:
new bisindole alkaloids from a deep-sea-derived actinomycete. Org Lett.
2012, 14(13), 3364-3367.
10. Saurav, K.; Zhang, W.; Saha, S.; Zhang, H.; Li, S.; Zhang, Q..; Wu, Z.;
Zhang, G.; Zhu, Y.; Verma, G. In silico molecular docking, preclinical
evaluation of spiroindimicins A-D, lynamicin A and D isolated from deep
marine sea derived Streptomyces sp. SCSIO 03032. Interdiscip Sci. 2014,
6(3), 187-196.
11. Zhang, W.; Ma, L.; Li, S.; Liu, Z.; Chen, Y.; Zhang, H.; Zhang, G.;
Zhang, Q.; Tian, X.; Yuan, C.; Zhang, S.; Zhang, W.; Zhang, C. Indimicins
A-E, Bisindole Alkaloids from the Deep-Sea-Derived Streptomyces sp.
SCSIO 03032. J. Nat. Prod. 2014, 77, 1887-1892.
12. Giannakouros, T.; Nikolakaki, E.; Mylonis, I.; Georgatsou, E. Serine-
arginine protein kinases: a small protein kinase family with a large cellular
presence. FEBS J. 2011, 278, 570-586.
25. Zhou, Z.; Fu, X.D. Regulation of splicing by SR proteins and SR protein-
specific kinases. Chromosoma, 2013, 122, 191-207.
13. Zhou, Z.; Fu, X.D. Regulation of splicing by SR proteins and SR protein-
specific kinases. Chromosoma 2013, 122, 191-207.
26. Fukuhara, T.; Hosoya, T.; Shimizu, S.; Sumi, K.; Oshiro, T.; Yoshinaka,
Y.; Suzuki, M.; Yamamoto, N.; Herzenberg, L.A.; Herzenberg, L.A.;
Hagiwara, M. Utilization of host SR protein kinases and RNA-splicing
machinery during viral replication. Proc. Natl. Acad. Sci. USA 2006, 103,
11329-11333.
27. Ngo, J.C.; Gullingsrud, J.; Giang, K.; Yeh, M.J.; Fu, X.D.; Adams, J.A.;
McCammon, J.A.; Ghosh, G. SR protein kinase 1 is resilient to inactivation.
Structure 2007, 15, 123-133.
14. (a) Crews, L.A.; Balaian, L.; Delos Santos N.P.; Leu, H.S.; Court, A.C.;
Lazzari, E.; Sadarangani, A.; Zipeto, M.A.; La Clair J.J.; Villa, R.; Kulidjian,
A.; Storb, R.; Morris, S.R.; Ball, E.D.; Burkart, M.D.; Jamieson, C.H. RNA
Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in
Secondary Human AML. Cell Stem Cell. 2016, 19(5), 599-612. (b) Palacino,
J.; Swalley, S.E.; Song, C.; Cheung, A.K.; Shu, L.; Zhang, X.; Van Hoosear,
M.; Shin, Y.; Chin, D.N.; Keller, C.G.; Beibel, M.; Renaud, N.A.; Smith,
T.M.; Salcius, M.; Shi, X.; Hild, M.; Servais, R.; Jain, M.; Deng, L.; Bullock,
C.; McLellan, M.; Schuierer, S.; Murphy, L.; Blommers, M.J.; Blaustein, C.;